A Food and Drug Administration-approved asthma therapeutic agent impacts amyloid ß in the brain in a transgenic model of Alzheimer disease.
J Biol Chem
; 290(4): 1966-78, 2015 Jan 23.
Article
in En
| MEDLINE
| ID: mdl-25468905
ABSTRACT
Interfering with the assembly of Amyloid ß (Aß) peptides from monomer to oligomeric species and fibrils or promoting their clearance from the brain are targets of anti-Aß-directed therapies in Alzheimer disease. Here we demonstrate that cromolyn sodium (disodium cromoglycate), a Food and Drug Administration-approved drug already in use for the treatment of asthma, efficiently inhibits the aggregation of Aß monomers into higher-order oligomers and fibrils in vitro without affecting Aß production. In vivo, the levels of soluble Aß are decreased by over 50% after only 1 week of daily intraperitoneally administered cromolyn sodium. Additional in vivo microdialysis studies also show that this compound decreases the half-life of soluble Aß in the brain. These data suggest a clear effect of a peripherally administered, Food and Drug Administration-approved medication on Aß economy, supporting further investigation of the potential long-term efficacy of cromolyn sodium in Alzheimer disease.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Peptide Fragments
/
Brain
/
Amyloid beta-Peptides
/
Cromolyn Sodium
/
Drug Approval
/
Alzheimer Disease
Limits:
Animals
/
Humans
Country/Region as subject:
America do norte
Language:
En
Journal:
J Biol Chem
Year:
2015
Document type:
Article